Click Therapeutics, Inc.
About Click Therapeutics, Inc.
Click Therapeutics, Inc. develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. The company creates Digital Therapeutics that combine clinical science with software to treat disease. It has advanced programs including CT-155, an investigational prescription digital therapeutic co-developed with Boehringer Ingelheim for schizophrenia symptoms, which received FDA Breakthrough Device designation. The company has also achieved FDA authorization for digital therapeutics targeting episodic migraine and major depressive disorder.
- 🔗 Click Therapeutics raises $50M and more funding news
- 🔗 Click Therapeutics Completes $52 Million Series B Financing Co-Led by H.I.G. BioHealth Partners and Accelmed Partners
- 🔗 Click Therapeutics - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 Click Therapeutics, Inc. Company Overview, Contact Details & Competitors | LeadIQ
- 🔗 Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
Key highlights
- Raised ~$50M Series D led by Boehringer Ingelheim to commercialize CT-155 for schizophrenia.
- CT-155 received FDA Breakthrough Device designation and was co-developed with Boehringer Ingelheim.
- Prior $52M Series B co-led by H.I.G. BioHealth Partners and Accelmed Partners.
- Achieved FDA authorization for digital therapeutics in migraine (CT-132) and major depressive disorder (Rejoyn).
- Total funding reported at $180M across multiple rounds with 17 institutional investors.
Ask StreetZero about Click Therapeutics, Inc.
Put our AI to work on this deal.
Similar companies
Other Other Health Care deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account